Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
5 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

2 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.

BEACON CRC: Strategies to manage treatment-related AEs

Roshini Claire Anthony
06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

“Gastrointestinal (GI) AEs, including diarrhoea, nausea, and vomiting, were among the most commonly reported AEs for encorafenib plus cetuximab,” noted study author Professor Josep Tabernero, director of the Vall d’Hebron Institute of Oncology, Barcelona, Spain. [ESMO GI 2020, abstract SO-21]

Nonetheless, they occurred less frequently in the encorafenib-cetuximab than the chemotherapy group and rarely led to dose modification or discontinuation.

Dietary modification could help manage these GI symptoms, as could increased fluid intake and dehydration prevention strategies. Loperamide could help with diarrhoea while antiemetics such as dexamethasone, 5-HT3 antagonists, lorazepam, and metoclopramide could help manage nausea or vomiting.

Incidents of myalgia or arthralgia were mostly mild or moderate in severity, resulting in few dose modifications and no discontinuations. Supportive care involved resting the painful areas, the use of pain relief, and stretching exercises.

Renal and urinary AEs were mostly mild or moderate, did not lead to dose modifications, and rarely led to discontinuations.

To combat these AEs, patients should be advised to maintain adequate fluid intake and avoid nephrotoxic medications where possible. Urinary tract infections should be treated promptly, and patients should be assessed for other causes of renal dysfunction, with a nephrologist consulted if necessary.

Fatigue, asthenia, headache, and pyrexia were also reported in the trial participants, though they rarely led to treatment modification or discontinuation, and could be treated with supportive care and symptom management.

For all these AEs, encorafenib should be permanently discontinued for recurrent grade 4 events. For recurrent grade 2 or first occurrence of any grade 3–4 AEs, encorafenib should be withheld for ≤4 weeks and resumed at reduced dose if improved to grade 0–1 or baseline levels, or permanently discontinued if no improvement.

Skin AEs were also common among encorafenib-cetuximab recipients but were mostly of mild or moderate intensity and rarely led to dose modification or discontinuation.

“In clinical practice, these events can be bothersome for some patients and we should ensure they have the best advice to manage them effectively,” said Tabernero.

Avoiding sun exposure, referral to a dermatologist, or a skin biopsy may be helpful. Management strategies also differ according to rash severity. Mild rash can be treated with topical corticosteroids (eg, mometasone cream) and/or topical antibiotics (eg, erythromycin), while moderate rash can be managed with topical erythromycin/clindamycin plus topical mometasone/pimecrolimus plus oral antibiotics. Oral prednisolone/isotretinoin can be considered for severe rash.

For skin toxicities other than hand-foot skin reactions, encorafenib dose modification may include permanent discontinuation for grade 4 AEs, while for grade 2–3 AEs, encorafenib should be withheld until grade 0–1, with original dose resumed if first occurrence or reduced dose for recurrent event.

The encorafenib-cetuximab combination has already demonstrated efficacy in improving overall survival (median 9.3 vs 5.9 months [standard chemotherapy*]; hazard ratio, 0.61) and objective response rate (20 percent vs 2 percent) in patients with previously treated BRAF V600E mutant mCRC. [ASCO 2020, abstract 4001]

Overall incidence of AEs was similar across treatment groups (grade 3 AEs: 57 percent [encorafenib-cetuximab] vs 64 percent [chemotherapy]), though median duration of treatment was longer in the former (19 vs 7 weeks).

“AEs that occurred with encorafenib plus cetuximab [in BEACON CRC] were generally manageable, reversible, and infrequently associated with treatment discontinuation,” noted Tabernero.

“Practical approaches to AE management can be employed by both patients and healthcare professionals to help mitigate the impact of these events,” he said.

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
5 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

2 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.